The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.
 
Jia (Jenny) Liu
Honoraria - MSD; Specialised Therapeutics
Consulting or Advisory Role - Greywolf Therapeutics (Inst); Starpharma (Inst)
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - ImmVirX; MSD; Starpharma
 
Anna Rachel Minchom
Honoraria - GlaxoSmithKline; Janssen; Merck; Seagen
Consulting or Advisory Role - Faron Pharmaceuticals; GlaxoSmithKline; Janssen Oncology; MSD
Research Funding - Astex Pharmaceuticals (Inst); Merck (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Alastair Greystoke
Consulting or Advisory Role - AstraZeneca; BMSi; Boehringer Ingelheim; Foundation Medicine; Guardant Health; Janssen; Lilly; MSD Oncology; Novartis; Pfizer; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Foundation Medicine; Janssen; Janssen; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); CV6 Therapeutics (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CV6 Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Exscientia (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Moderna Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - iOnctura (Inst); Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Debashis Sarker
Honoraria - Bayer; Ipsen
Consulting or Advisory Role - AAA HealthCare; Abbvie; AstraZeneca; Bayer; Eisai; Incyte; Ipsen; MSD Oncology; Novartis; Roche; Sirtex Medical; UCB (Inst)
Speakers' Bureau - AstraZeneca; Bayer; Eisai; Incyte; SERVIER
Research Funding - Inspirata (Inst); UCB (Inst)
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Ipsen
(OPTIONAL) Uncompensated Relationships - Medivir; MINA THERAPEUTICS
 
Anthony M. Joshua
Stock and Other Ownership Interests - Opthea; Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Medison (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
Cienne Morton
Honoraria - MSD
Travel, Accommodations, Expenses - SERVIER
 
Burak Y Aktas
No Relationships to Disclose
 
Rasha Cosman
No Relationships to Disclose
 
Dominika Chwialkowska
No Relationships to Disclose
 
Jeremy Paull
Employment - Starpharma
Leadership - Starpharma
Stock and Other Ownership Interests - Starpharma
Patents, Royalties, Other Intellectual Property - Patents for dendrimer technology generated as part of employment, owned by Starpharma.
 
Nicola Jane Main
Employment - Starpharma
Stock and Other Ownership Interests - Starpharma
 
Bernadette Marie Jean-Francois
Employment - Starpharma
Patents, Royalties, Other Intellectual Property - Starpharma
 
Julia Le Meur
Employment - Starpharma
 
Stephanie Ruth Edmondson
Employment - Starpharma
Stock and Other Ownership Interests - Starpharma
Patents, Royalties, Other Intellectual Property - Starpharma
 
Natalie Cook
Employment - CellCentric (I)
Stock and Other Ownership Interests - CellCentric (I)
Honoraria - Roche
Speakers' Bureau - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Loxo/Lilly (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); UCB (Inst)
Patents, Royalties, Other Intellectual Property - CUPiD Methylation assay. Patent application has now been filed at the UKIPO. The patent application number is GB2317261.2 (Inst)
Travel, Accommodations, Expenses - Roche
(OPTIONAL) Uncompensated Relationships - Roche